Study identifier:NIS-NRU-ATC-2013/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Retrospective observational study to estimate the duration of initial antidepressant treatment in patients with recurrent depressive disorder who demonstrated a suboptimal response to therapy: DIANA Study
Major depressive episode
N/A
No
-
All
450
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2014 by AstraZeneca
AstraZeneca
-
This Non-Interventional Study (NIS) is intended to evaluate the duration of treatment with an initial antidepressant taken as monotherapy in patients in whom treatment was changed because of suboptimal response at physician’s discretion. This will address unmet medical needs of patients with a depressive episode related to RDD (ICD-10, Version 2010), who have failed to respond adequately to initial treatment with an antidepressant and contribute to an understanding of the usual approaches that physicians adopt to monitor initial treatment efficacy in RDD (Recurrent Depressive Disorder). The study will also focus on second-line therapy in hard to treat patients, describing the different pharmacotherapeutic strategies.
Location
Location
Moscow, Russian Federation
Location
Nizhniy Novgorod, Russian Federation
Location
Yaroslavl, Russian Federation
Location
Saint-Petersburg, Russian Federation
Location
Stavropol, Russian Federation
Location
Rostov-on-Don, Russian Federation
Location
Kazan, Russian Federation
Location
Ivanovo, Russian Federation
Arms | Assigned Interventions |
---|---|
patients with major depression Inpatients and outpatients diagnosed with an episode of major depression relating to RDD (ICD-10, Version 2010) during the period from January 1, 2012 till September 30, 2013. Initially treated with antidepressant monotherapy, using a flexible dosage regimen if required, for at least 2 week | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.